Methoxy Polyethylene Glycol-Epoetin Beta
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09107 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary release disorder of platelets | KG + DL |
| 2 | Glanzmann thrombasthenia | KG + DL |
| 3 | pseudo-von Willebrand disease | KG + DL |
| 4 | severe nonproliferative diabetic retinopathy | KG + DL |
| 5 | heparin cofactor 2 deficiency | KG + DL |
| 6 | antithrombin deficiency type 2 | KG + DL |
| 7 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 8 | thrombophilia | KG + DL |
| 9 | diabetic retinopathy | KG + DL |
| 10 | HER2 positive breast carcinoma | KG + DL |
| 11 | plasma cell myeloma | KG + DL |
| 12 | hemoglobinopathy | KG + DL |
| 13 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 14 | plasmacytoma | KG + DL |
| 15 | seborrheic dermatitis | KG + DL |
| 16 | indolent plasma cell myeloma | KG + DL |
| 17 | psoriasis | KG + DL |
| 18 | progesterone-receptor positive breast cancer | KG + DL |
| 19 | normal breast-like subtype of breast carcinoma | KG + DL |
| 20 | neurolymphomatosis | KG + DL |
| 21 | breast tumor luminal A or B | KG + DL |
| 22 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 23 | progesterone-receptor negative breast cancer | KG + DL |
| 24 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 25 | pyropoikilocytosis, hereditary | KG + DL |
| 26 | beta-thalassemia with other manifestations | KG + DL |
| 27 | drug-induced osteoporosis | KG + DL |
| 28 | pyruvate kinase deficiency of red cells | KG + DL |
| 29 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 30 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 31 | dermatitis | KG + DL |
| 32 | Scott syndrome | KG + DL |
| 33 | autosomal dominant macrothrombocytopenia | KG + DL |
| 34 | penile fibromatosis | KG + DL |
| 35 | platelet-type bleeding disorder | KG + DL |
| 36 | Ledderhose disease | KG + DL |
| 37 | pityriasis lichenoides | KG + DL |
| 38 | hyperthyroidism | KG + DL |
| 39 | parapsoriasis | KG + DL |
| 40 | infantile digital fibromatosis | KG + DL |
| 41 | acrodermatitis chronica atrophicans | KG + DL |
| 42 | bronchitis | KG + DL |
| 43 | palmar fibromatosis | KG + DL |
| 44 | neonatal dermatomyositis | KG + DL |
| 45 | polycythemia (disease) | KG + DL |
| 46 | Ehlers-Danlos syndrome, fibronectinemic type | KG + DL |
| 47 | hydroa vacciniforme, familial | KG + DL |
| 48 | acne keloid | KG + DL |
| 49 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 50 | amenorrhea (disease) | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.